Compare Bristol-Myers Squibb Co (BMY) vs LTC Properties Inc (LTC) Price & Performance

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

LTC Properties (LTC) trades at $38.69, down 1.85% over 24 hours, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported Q2 2026 earnings that beat expectations, with EPS of $0.56 versus $0.48 expected, and continues aggressive SHOP portfolio expansion, with recent acquisitions totaling over $285 million year-to-date. Revenue grew to $262.85 million in 2025, and net income margin remains strong at 38.93%, though recent quarters show mixed earnings performance.

LTC presents a mixed outlook; strong fundamentals and dividend yield near 5.9% appeal to income investors, but bearish technicals and elevated debt levels pose risks. Analyst consensus is cautious with 59% hold ratings, reflecting concerns over execution amid rapid portfolio growth. Key catalysts include SHOP acquisition success and demographic tailwinds, while risks involve interest rate sensitivity and integration challenges.